Chairs: Masatoshi Kudo, MD, PhD (Japan) and Kwang-Hyub Han, MD (Republic of Korea)
Transarterial chemoembolization (TACE) and Y90-radioembolization (Y90) are at the core of the treatment of patients with hepatocellular carcinoma who cannot receive potentially curative therapies such as transplantation, resection or percutaneous ablation.